Skip to main content
Top
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Erratum

Erratum to: Bone-stromal cells up-regulate tumourigenic markers in a tumour-stromal 3D model of prostate cancer

Authors: Louisa CE Windus, Tristan T Glover, Vicky M Avery

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Excerpt

After the publication of this work [1] the authors’ informed the journal editors that Figure two (Figure 1 here) (B) is mislabelled and is a replica of Figure three(D). The correct version of Figure two(B) (Figure 1 here) is given below.
Appendix
Available only for authorised users
Literature
1.
go back to reference Windus LC, Glover TT, Avery VM: Bone-stromal cells up-regulate tumourigenic markers in a tumour-stromal 3D model of prostate cancer. Mol Cancer. 2013, 12: 112- 10.1186/1476-4598-12-112PubMedCentralCrossRefPubMed Windus LC, Glover TT, Avery VM: Bone-stromal cells up-regulate tumourigenic markers in a tumour-stromal 3D model of prostate cancer. Mol Cancer. 2013, 12: 112- 10.1186/1476-4598-12-112PubMedCentralCrossRefPubMed
Metadata
Title
Erratum to: Bone-stromal cells up-regulate tumourigenic markers in a tumour-stromal 3D model of prostate cancer
Authors
Louisa CE Windus
Tristan T Glover
Vicky M Avery
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-188

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine